医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Innovus Pharmaceuticals Expands Its International Proprietary Product Patent Portfolio with Its First Chinese Patent

2017年10月11日 PM07:00
このエントリーをはてなブックマークに追加


 

SAN DIEGO

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today that it received Notification to Grant a Patent Right for Sensum+®, its product to improve male penile sensitivity, from the Chinese State Intellectual Property Office (“SIPO”). Innovus Pharma has currently fourteen (14) issued patents and eight (8) patent applications covering several of its products and has licensed in an additional four (4) patents and five (5) patent applications from third parties covering additional products.

“I am very excited about the expansion of our patent coverage for Sensum+®, one of our important core products, into China,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “This represents the first patent that we have received in China and we look forward to expanding the sale of our products there either through our working with a distributor or distributors in China or through our direct selling efforts.”

About Sensum+®

Sensum+® is a non-medicated cream which moisturizes the head and shaft of the penis for enhanced feelings of sensation and greater sexual satisfaction. It is a patented blend of essential oils and ingredients generally recognized as safe that recently commenced marketing in the U.S. Innovus Pharma acquired the global ex-U.S. distribution rights to Sensum+® from Centric Research Institute. The safety and efficacy of Sensum+® was evaluated in two post-marketing survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+® twice daily for 14 consecutive days followed by once daily for eight weeks and as needed thereafter. Study participants reported a ~50% increase in penile sensitivity with the use of Sensum+®.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly; (b) commercial partners to primary care physicians, urologists, gynecologists and therapists; and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com, www.zestra.com, www.ejectdelay.com, www.myvesele.com, www.sensumplus.com, www.myandroferti.com, www.fluticare.com, www.beyondhumantestosterone.com, www.getbeyondhuman.com, www.trybeyondhuman.com, www.prostagorx.com and www.allervarx.com.

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to successfully commercialize Sensum+® and other products and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171011005247/en/

CONTACT

Emerging Markets LLC
James S. Painter, 407-340-0226
jamespainter@emergingmarketsllc.com
or
Chesapeake
Group
410-825-3930
info@chesapeakegp.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan
  • Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″